Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4- one, in mice

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 4, 2009, Pages 615-625

  Guo, Jianxia ^a   Parise, Robert A ^a   Joseph, Erin ^a   Egorin, Merrill J ^a   Lazo, John S ^a   Prochownik, Edward V ^b   Eiseman, Julie L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

c Myc; c Myc Max inhibitor; Cancer; Protein protein disruptor; Thioxothiazolidinone

Indexed keywords

10058 F4; 5 (4 ETHYLBENZYLIDINE) 2 THIOXOTHIAZOLIDIN 4 ONE; MAX PROTEIN; MYC PROTEIN; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DIMERIZATION; FEMALE; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THIAZOLES; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58849157916     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0774-y     Document Type: Article

References (28)

1. X Yin C Giap JS Lazo EV Prochownik 2003 Low molecular weight inhibitors of Myc/Max interaction and function Oncogene 22 6151 6159
2. KA Blum G Lozanski JC Byrd 2004 Adult Burkitt leukemia and lymphoma Blood 104 3009 3020
3. AL Shaffer G Wright L Yang J Powell V Ngo L Lamy LT Lam RE Davis LM Staudt 2006 A library of gene expression signatures to illuminate normal and pathological lymphoid biology Immunol Rev 210 67 85
4. EM Berns JG Klijn M Smid IL van Staveren MP Look WL van Putten JA Foekens 1996 TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients Genes Chromosomes Cancer 16 170 179
5. CM Schlotter U Vogt U Bosse B Mersch K Wassmann 2003 c-Myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer Breast Cancer Res 5 R30 R36
6. D Arango JM Mariadason AJ Wilson W Yang GA Corner MJ Aranes LH Augenlicht 2003 C-Myc overexpression sensitizes colon cancer cells to camptothecin-induced apoptosis Br J Cancer 89 1757 1765
7. I Gomez-Curet RS Perkins R Bennett KL Feidler SP Dunn LJ Kruger 2006 c-Myc inhibition negatively impacts lymphoma growth J Pediatr Surg 41 207 211
8. MJ Huang YC Cheng CR Liu S Lin E Liu 2006 A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia Exp Hematol 34 1480 1489
9. CP Lin JD Liu JM Chow CR Liu HE Liu 2007 Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells Anticancer Drugs 18 161 170
10. VB Sampson NH Rong J Han Q Yang V Aris P Soteropoulos NJ Petrelli SP Dunn LJ Krueger 2007 MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitts lymphoma cells Cancer Res 67 9762 9770
11. J Gil P Kerai M Lleonart D Bernard JC Cigudosa G Peters A Carnero D Beach 2005 Immortalization of primary human prostate epithelial cells by c-Myc Clin Cancer Res 65 2179 2185
12. C Leonetti A Biroccio C D'Angelo SC Semple M Scarsella G Zupi 2007 Therapeutic Integration of c-Myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer Prostate 67 1475 1485
13. NN Nupponen L Kakkola P Koivisto T Visakorpi 1998 Genetic alterations in hormone-refractory recurrent prostate carcinomas Am J Pathol 153 141 148
14. EM McGiffie CV Catapano 2002 Design of a novel triple helix forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene Nucleic Acids Res 30 2701 2709
15. T Berg SB Cohen J Desharnais C Sonderegger DJ Maslyar J Goldberg DL Boger PK Vogt 2002 Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts Proc Natl Acad Sci USA 99 3830 3835
16. D'Argenio DZ, Schumitzky A (eds) (1997) ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. University of Southern California, Los Angeles
17. H Akaike 1979 A Bayesian extension of the minimal AIC procedures of autoregressive model fitting Biometrika 66 237 242
18. ML Rocci WJ Jusko 1983 LAGRAN program for area and moments in pharmacokinetic analysis Comput Programs Biomed 16 203 216
19. M Jain C Arvanitis K Chu W Dewey E Leonahardt M Trinh CD Sundberg M Bishop DW Felsher 2002 Sustained loss of a neoplastic phenotype by brief inactivation of MYC Science 297 102 104
20. G Cutrona EM Carpaneto A Ponzanelli M Uliva E Millo S Scarfi S Roncella U Benatti LC Boffa M Ferrarini 2003 Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA Complementary to the Eμ Enhancer Cancer Res 63 6144 6148
21. YH Wang S Liu G Zhang CQ Zhou HX Zhu XB Zhou LP Quan JF Bai NZ Xu 2005 Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo Breast Cancer Res 7 R220 R228
22. L Shen C Zhang JL Ambrus JH Wang 2005 Silencing of human c-myc oncogene expression by poly-DNP-RNA Oligonucleotides 15 23 35
23. A Siddiqui-Jain CL Grand DJ Bearss LH Hurley 2002 Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-Myc transcription Proc Natl Acad Sci USA 99 11593 11598
24. H Wang DI Hammoudeh AV Follis BE Reese JS Lazo SJ Metallo EV Prochownik 2007 Improved low molecular weight Myc-Max inhibitors Mol Cancer Ther 6 2399 2408
25. D Xiao X Qu C Weber 2002 GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells Regulatory Peptides 109 141 148
26. G Cassinelli R Supino V Zuco C Lanzi AI Scovassi SC Semple F Zunino 2004 Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel Biochem Pharmacol 68 923 932
27. D Bernard A Pourtier-Manzanedo J Gil DH Beach 2003 Myc confers androgen-independent prostate cancer cell growth J Clin Invest 112 1724 1737
28. I Yoshimura JM Wu Y Chen C Ng C Mallouh JM Backer CE Mendola H Tazaki 1995 Effects of 5-α-Dihydrotestosterone (DHT) on the transcription of nm23 and c-myc genes in human prostatic LNCaP cells Biochem Biophy Res Commun 208 603 609